skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone

Review

(2477) Views  (566) Full article downloads

Authors: José Mª Ruiz-Moreno, Javier A Montero

Published Date March 2008 Volume 2008:2(1) Pages 71 - 75
DOI: http://dx.doi.org/10.2147/OPTH.S1643

José Mª Ruiz-Moreno1,2, Javier A Montero2

1Department of Ophthalmology, Miguel Hernández University School of Medicine, Alicante, Spain; 2Vitreo-Retinal Unit, Alicante Institute of Ophthalmology, Alicante, Spain

Abstract: Choroidal neovascularization (CNV) secondary to age related macular degeneration is among the leading causes of legal blindness in developed countries. Photodynamic therapy (PDT) with verteporfin induces CNV closure causing little damage to healthy tissue, but the need to re-treat may lead to low final visual acuity at an unacceptable cost. The association of intravitreous triamcinolone or antiangiogenic drugs with PDT has been used in order to reduce these limitations of the therapy. The combination of PDT and intravitreous triamcinolone, its complications and outcome at one and two-year follow-up are discussed.

Keywords: age related macular degeneration, choroidal neovascularization, photodynamic therapy, steroid, triamcinolone








Readers of this article also read:

An intractable case of Pseudomonas aeruginosa infection after scleral buckling for rhegmatogenous retinal detachment
Histology of corneal wound healing after deep lamellar endothelial keratoplasty
Automated detection of proliferative retinopathy in clinical practice
Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
Treatment of age-related macular degeneration: focus on ranibizumab
Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
Emerging treatment options in the management of non-small cell lung cancer
Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review
Afatinib treatment in advanced non-small cell lung cancer